Benefits
Energy and workout claims compared with the human research
Eria jarensis products are sold for energy, focus, mood and workout drive, but no controlled human trial of oral DMPEA has been published. The researchers who tested these products said they knew of no human research supporting it for athletic performance. Any effect people notice cannot be separated from the caffeine and other stimulants these products usually contain.
What laboratory testing found inside Eria jarensis products
Product analysis only. None of 12 US products labeled with the orchid was accurately labeled. Products listing caffeine held 0.1 to 665 mg per serving, four held an undeclared stimulant, and two held the FDA-prohibited stimulant 1,4-DMAA. News summaries of the study report DMPEA at 0.1 to 41 mg per serving in about two thirds and none in one third.
Whether the orchid is the real source of the DMPEA
The orchid is promoted as a major natural source of DMPEA, yet no published chemical analysis of the plant shows that it contains the compound. Given the amounts found in products, the researchers who tested them judged it highly unlikely that the DMPEA was extracted from the orchid. A consumer testing site's summary adds that the compound may have been added to the products with the highest amounts.
Adrenergic and trace amine receptor activity in cell assays
Laboratory work only. In cells engineered to carry human receptors, DMPEA weakly activated two alpha-1 adrenergic receptor subtypes (about 8% to 19% of the adrenaline maximum) and activated the trace amine receptor TAAR1 at 64% of the phenethylamine maximum, at micromolar concentrations. No human study has linked these findings to any effect of a supplement.
Blood vessel contraction in isolated rat arteries
Animal tissue only. In aorta segments from rats, DMPEA caused concentration-dependent contraction (EC50 148 micromolar), much weaker than synephrine or phenethylamine, and it produced smaller, variable contraction of renal arteries and none in mesenteric arteries. The authors warned that such compounds may affect blood pressure in people.
Brain uptake and breakdown in radiotracer studies
Tracer research, not supplement use. Injected radiolabeled DMPEA entered the mouse brain quickly and was broken down there by the enzyme MAO-B, and a PET scan study showed the tracer accumulating in the human brain. These tracer amounts were given by injection to measure MAO-B activity and say nothing about the effects of oral supplements.
Mechanism of action
Weak partial agonist at alpha-1 adrenergic receptors and TAAR1
In human receptor cell assays, DMPEA was a weak partial agonist at alpha-1B and alpha-1D adrenergic receptors (EC50 6.1 and 8.4 micromolar) and activated TAAR1 (EC50 21 micromolar). In rat aorta its contraction was partly blocked by the alpha-1 blocker prazosin and shifted by a TAAR1 blocker. All of this is laboratory and animal tissue work.
Breakdown by monoamine oxidase B
In mice, DMPEA was a selective substrate of brain MAO-B: its breakdown was reduced by the MAO-B inhibitor deprenyl (selegiline) but not appreciably by the MAO-A inhibitor clorgyline. This is why the radiolabeled form was used as a tracer for MAO-B activity. Whether MAO inhibitors raise DMPEA levels in people has not been studied.
Absorption and dose predictions from computer modeling
A modeling study combined gut cell, human liver fraction and receptor data to predict that DMPEA is well absorbed and cleared by the liver, and estimated the oral doses needed for half-maximal receptor activation at about 4 to 6 mg/kg (alpha-1) and 14 mg/kg (TAAR1). These are computer predictions, not measurements in people.
Clinical trials
Laboratory analysis by liquid chromatography with high-resolution mass spectrometry of sports supplements bought online in the US and labeled as containing the orchid Eria jarensis. (Cohen et al. 2025, Clin Toxicol)
12 US sports supplement products (powders and pills); no human participants.
None of the 12 products was accurately labeled; amounts of caffeine, theobromine, hordenine, yohimbine, DMPEA and synephrine differed from labels. Products listing caffeine held 0.1 to 665 mg per serving. Nine of 12 listed an ingredient that was not detected or held an unlisted stimulant, four held an undeclared stimulant, and two contained the FDA-prohibited stimulant 1,4-DMAA. News reports of the full paper give DMPEA at 0.1 to 41 mg per serving.
In vitro study of phenethylamine and alkylamine supplement ingredients in cell lines overexpressing human adrenergic receptor subtypes or TAAR1. (Pinckaers et al. 2024, Nutrients)
Engineered human receptor cell lines; no human participants.
DMPEA acted as a weak agonist at the alpha-1B and alpha-1D adrenergic receptors (EC50 6.1 and 8.4 micromolar; maximal effect 19% and 7.9% of adrenaline) and activated TAAR1 (EC50 21 micromolar; 64% of the phenethylamine maximum). Several other supplement amines were far more potent at adrenergic receptors. Laboratory findings only.
Physiologically based kinetic modeling with reverse dosimetry, using gut cell permeability, human liver S9 metabolism and the earlier receptor data, for 12 phenethylamine analogues. (Pinckaers et al. 2025, Arch Toxicol)
Computer model of a 70 kg adult built from cell and liver fraction experiments; no human participants.
DMPEA crossed a gut cell layer readily and was metabolized by human liver fractions. Predicted oral doses for half-maximal activation were 4.07 mg/kg (alpha-1B), 5.60 mg/kg (alpha-1D) and 14.0 mg/kg (TAAR1). The authors ranked higenamine, isopropyloctopamine, BMPEA and synephrine, not DMPEA, as the highest priorities for risk assessment. Predictions, not measurements.
Wire myograph study of isolated mesenteric artery, renal artery and aorta segments from 20 Wistar Kyoto rats, testing 12 phenethylamine and 4 alkylamine supplement ingredients, with an alpha-1 blocker or TAAR1 blocker. (Pinckaers et al. 2026, Cardiovasc Toxicol)
Artery segments from 11 male and 9 female rats; no human participants.
DMPEA contracted aorta segments (EC50 148 micromolar; 86.5% of the phenylephrine maximum), with smaller and variable renal artery contraction and no mesenteric artery response. Prazosin partly blocked the aorta effect and a TAAR1 blocker shifted it. DMPEA was far less potent than synephrine (0.906 micromolar) or phenethylamine (5.57 micromolar).
Radiotracer study of carbon-14 labeled DMPEA in mice, with MAO-B and MAO-A inhibitor pretreatment and in vitro brain enzyme tests. (Inoue et al. 1985, J Neurochem)
Mice; no human participants.
Labeled DMPEA entered the brain quickly (about 10% of the injected dose per gram of brain). Its breakdown product fell in proportion to MAO-B inhibition by deprenyl but was not appreciably reduced by the MAO-A inhibitor clorgyline, showing DMPEA is a selective MAO-B substrate in mouse brain.
Development of carbon-11 labeled DMPEA as a PET tracer for brain MAO-B, with biodistribution in mice and PET imaging in people after intravenous injection. (Shinotoh et al. 1987, J Nucl Med)
Mice and human PET subjects (number not given in the abstract); tracer amounts only.
In mice, brain uptake peaked 1 minute after intravenous injection and then declined. In the human brain, radioactivity rose gradually over 60 minutes after rapid initial uptake, highest in the basal ganglia and thalamus. This shows the tracer reaches the human brain; it does not test any effect of oral supplement doses.